Fibroadenoma secondary prevention: Difference between revisions

Jump to navigation Jump to search
Ifeoma odukwe (talk | contribs)
Ifeoma odukwe (talk | contribs)
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Fibroadenoma}}
{{Fibroadenoma}}
{{CMG}}; {{AE}}  
{{CMG}}; {{AE}} {[IO}}


==Overview==
==Overview==

Revision as of 14:11, 16 September 2019

Fibroadenoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fibroadenoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT Scan

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Fibroadenoma secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fibroadenoma secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fibroadenoma secondary prevention

CDC on Fibroadenoma secondary prevention

Fibroadenoma secondary prevention in the news

Blogs on Fibroadenoma secondary prevention

Directions to Hospitals Treating Fibroadenoma

Risk calculators and risk factors for Fibroadenoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: {[IO}}

Overview

There are no established measures for the secondary prevention of fibroadenoma.

Secondary Prevention

There are no established measures for the secondary prevention of fibroadenoma.

References

Template:WH Template:WS